Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2020

01-12-2020 | Helicobacter Pylori | Research article

Association of Helicobacter pylori babA2 gene and gastric cancer risk: a meta-analysis

Authors: Marce-Amara Kpoghomou, Jinchen Wang, Tianpei Wang, Guanfu Jin

Published in: BMC Cancer | Issue 1/2020

Login to get access

Abstract

Background

The association of Helicobacter pylori (H. pylori) babA2 gene with gastric cancer (GC) was reported by several studies, but results were inconsistent. This meta-analysis was performed to investigate the relationship between H. pylori babA2 gene and GC risk.

Methods

Case-control studies involving the association between H. pylori babA2 gene and GC risk were systematically identified from PubMed databases. A meta-analysis was used to pool studies and to estimate odds ratios (ORs) with 95% confidence intervals (CIs) of H. pylori babA2 gene associated with GC risk.

Results

Twenty studies were identified with a total of 1289 GC cases and 1081 controls. H. pylori babA2 gene was associated with an increased risk of GC by 2.05 fold (95% CI, 1.30–3.24, P = 0.002). In subgroup analysis, we found that H. pylori babA2 gene was significantly associated with GC risk in Asian population (OR = 2.63, 95% CI: 1.36–5.09 P = 0.004) but not in South American population (OR = 1.35, 95% CI: 0.69–2.64, P = 0.379).

Conclusions

This meta-analysis indicates that H. pylori babA2 gene may be associated with increased risk of GC, especially in Asian population.
Appendix
Available only for authorised users
Literature
1.
Bray F, et al. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer. 2013;132(5):1133–45.PubMedCrossRef
2.
Bertuccio P, et al. Recent patterns in gastric cancer: a global overview. Int J Cancer. 2009;125(3):666–73.PubMedCrossRef
3.
Sigon R, Canzonieri V, Rossi C. Early gastric cancer: a single-institution experience on 60 cases. Suppl Tumori. 2003;2(5):S23–6.PubMed
4.
5.
Ferlay J, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86.PubMedCrossRef
6.
7.
8.
Correa P, Piazuelo MB. Helicobacter pylori infection and gastric adenocarcinoma. US Gastroenterol Hepatol Rev. 2011;7(1):59–64.PubMedPubMedCentral
9.
Wroblewski LE, Peek RM, Wilson KT. Helicobacter pylori and gastric cancer: factors that modulate disease risk. Clin Microbiol Rev. 2010;23(4):713–39.PubMedPubMedCentralCrossRef
10.
11.
IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Schistosomes, liver flukes and helicobacter pylori. Lyon, 7–14 June 1994. IARC Monogr Eval Carcinog Risks Hum. 1994;61:1–241.
12.
Shiota S, et al. Systematic review and meta-analysis: the relationship between the helicobacter pylori dupA gene and clinical outcomes. Gut Pathog. 2010;2(1):13.PubMedPubMedCentralCrossRef
13.
Costa AC, Figueiredo C, Touati E. Pathogenesis of helicobacter pylori infection. Helicobacter. 2009;14(Suppl 1):15–20.PubMedCrossRef
14.
Queiroz DM, et al. Factors associated with helicobacter pylori infection by a cagA-positive strain in children. J Infect Dis. 2000;181(2):626–30.PubMedCrossRef
15.
Blaser MJ, et al. Infection with helicobacter pylori strains possessing cagA is associated with an increased risk of developing adenocarcinoma of the stomach. Cancer Res. 1995;55(10):2111–5.PubMed
16.
Atherton JC, et al. Mosaicism in vacuolating cytotoxin alleles of helicobacter pylori. Association of specific vacA types with cytotoxin production and peptic ulceration. J Biol Chem. 1995;270(30):17771–7.PubMedCrossRef
17.
Zambon CF, et al. Helicobacter pylori virulence genes and host IL-1RN and IL-1beta genes interplay in favouring the development of peptic ulcer and intestinal metaplasia. Cytokine. 2002;18(5):242–51.PubMedCrossRef
18.
Yamaoka Y, et al. Relationship between helicobacter pylori iceA, cagA, and vacA status and clinical outcome: studies in four different countries. J Clin Microbiol. 1999;37(7):2274–9.PubMedPubMedCentralCrossRef
19.
Yamaoka Y, et al. Importance of helicobacter pylori oipA in clinical presentation, gastric inflammation, and mucosal interleukin 8 production. Gastroenterology. 2002;123(2):414–24.PubMedCrossRef
20.
Su YL, et al. Combination of OipA, BabA, and SabA as candidate biomarkers for predicting helicobacter pylori-related gastric cancer. Sci Rep. 2016;6:36442.PubMedPubMedCentralCrossRef
21.
Souod N, et al. The study of the oipA and dupA genes in helicobacter pylori strains and their relationship with different gastroduodenal diseases. Gastroenterol Hepatol Bed Bench. 2015;8(Suppl 1):S47–53.PubMedPubMedCentral
22.
Liu J, et al. Association of presence/absence and on/off patterns of helicobacter pylori oipA gene with peptic ulcer disease and gastric cancer risks: a meta-analysis. BMC Infect Dis. 2013;13:555.PubMedPubMedCentralCrossRef
23.
Ilver D, et al. Helicobacter pylori adhesin binding fucosylated histo-blood group antigens revealed by retagging. Science. 1998;279(5349):373–7.PubMedCrossRef
24.
Boren T, et al. Attachment of helicobacter pylori to human gastric epithelium mediated by blood group antigens. Science. 1993;262(5141):1892–5.PubMedCrossRef
25.
Bartpho TS, et al. Precancerous gastric lesions with helicobacter pylori vacA (+)/babA2(+)/oipA (+) genotype increase the risk of gastric cancer. Biomed Res Int. 2020;2020:7243029.PubMedPubMedCentralCrossRef
26.
Roman-Roman A, et al. Helicobacter pylori vacA s1m1 genotype but not cagA or babA2 increase the risk of ulcer and gastric cancer in patients from southern Mexico. Gut Pathog. 2017;9:18.PubMedPubMedCentralCrossRef
27.
Heidari K, et al. The prevalence of helicobacter pylori virulence related genes (hpa and babA2) in Iranian patients with gastrointestinal disorders. Jundishapur J Microbiol. 2017;10(12):e60947.CrossRef
28.
Mottaghi B, et al. Helicobacter pylori vacA i region polymorphism but not babA2 status associated to gastric cancer risk in northwestern Iran. Clin Exp Med. 2016;16(1):57–63.PubMedCrossRef
29.
Abdi E, et al. Helicobacter pylori babA2 positivity predicts risk of gastric cancer in Ardabil, a very high-risk area in Iran. Asian Pac J Cancer Prev. 2016;17(2):733–8.PubMedCrossRef
30.
Talebi Bezmin Abadi A, et al. High correlation of babA 2-positive strains of helicobacter pylori with the presence of gastric cancer. Intern Emerg Med. 2013;8(6):497–501.PubMedCrossRef
31.
Saxena A, et al. Virulence attributes of helicobacter pylori isolates & their association with gastroduodenal disease. Indian J Med Res. 2011;133:514–20.PubMedPubMedCentral
32.
33.
Ghasemian Safaei H, et al. Relation of bab A2 genotype of helicobacter pylori infection with chronic active gastritis, duodenal ulcer and non-cardia active gastritis in Alzahra hospital Isfahan, Iran. Jundishapur J Microbiol. 2010;3(3):93–8.
34.
Bartchewsky W Jr, et al. Effect of helicobacter pylori infection on IL-8, IL-1beta and COX-2 expression in patients with chronic gastritis and gastric cancer. Scand J Gastroenterol. 2009;44(2):153–61.PubMedCrossRef
35.
36.
Erzin Y, et al. Role of host interleukin 1beta gene (IL-1B) and interleukin 1 receptor antagonist gene (IL-1RN) polymorphisms in clinical outcomes in helicobacter pylori-positive Turkish patients with dyspepsia. J Gastroenterol. 2008;43(9):705–10.PubMedCrossRef
37.
Chomvarin C, et al. Prevalence of helicobacter pylori vacA, cagA, cagE, iceA and babA2 genotypes in Thai dyspeptic patients. Int J Infect Dis. 2008;12(1):30–6.PubMedCrossRef
38.
Lee HS, et al. Expression of Lewis antigens and their precursors in gastric mucosa: relationship with helicobacter pylori infection and gastric carcinogenesis. J Pathol. 2006;209(1):88–94.PubMedCrossRef
39.
Han YH, et al. Clinical relevance of iceA and babA2 genotypes of helicobacter pylori in a Shanghai population. Chin J Dig Dis. 2004;5(4):181–5.PubMedCrossRef
40.
Oliveira AG, et al. babA2- and cagA-positive helicobacter pylori strains are associated with duodenal ulcer and gastric carcinoma in Brazil. J Clin Microbiol. 2003;41(8):3964–6.PubMedPubMedCentralCrossRef
41.
Mizushima T, et al. Clinical relevance of the babA2 genotype of helicobacter pylori in Japanese clinical isolates. J Clin Microbiol. 2001;39(7):2463–5.PubMedPubMedCentralCrossRef
42.
Gerhard M, et al. Clinical relevance of the helicobacter pylori gene for blood-group antigen-binding adhesin. Proc Natl Acad Sci U S A. 1999;96(22):12778–83.PubMedPubMedCentralCrossRef
43.
Wells G, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of case-control studies in meta-analyses, vol. 25; 2011. p. 603–5.
44.
Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–58.PubMedCrossRef
45.
Cochran WG. The combination of estimates from different experiments. Biometrics. 1954;10(1):101–29.CrossRef
46.
47.
48.
Pormohammad A, et al. Risk of gastric cancer in association with helicobacter pylori different virulence factors: a systematic review and meta-analysis. Microb Pathog. 2018;118:214–9.PubMedCrossRef
49.
50.
51.
52.
Maeda S, et al. Relationship between nuclear factor-kappaB activation and virulence factors of helicobacter pylori in Japanese clinical isolates. J Gastroenterol Hepatol. 2002;17(5):556–62.PubMedCrossRef
53.
Kuipers EJ, et al. Long-term sequelae of helicobacter pylori gastritis. Lancet. 1995;345(8964):1525–8.PubMedCrossRef
54.
Dhar SK, et al. Molecular mechanism of action of major helicobacter pylori virulence factors. Mol Cell Biochem. 2003;253(1–2):207–15.PubMedCrossRef
55.
Zambon CF, et al. Helicobacter pylori babA2, cagA, and s1 vacA genes work synergistically in causing intestinal metaplasia. J Clin Pathol. 2003;56(4):287–91.PubMedPubMedCentralCrossRef
56.
Marshall DG, et al. Genomic DNA fingerprinting of clinical isolates of helicobacter pylori using short oligonucleotide probes containing repetitive sequences. J Appl Bacteriol. 1996;81(5):509–17.PubMed
57.
Akopyanz N, et al. DNA diversity among clinical isolates of helicobacter pylori detected by PCR-based RAPD fingerprinting. Nucleic Acids Res. 1992;20(19):5137–42.PubMedPubMedCentralCrossRef
Metadata
Title
Association of Helicobacter pylori babA2 gene and gastric cancer risk: a meta-analysis
Authors
Marce-Amara Kpoghomou
Jinchen Wang
Tianpei Wang
Guanfu Jin
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2020
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-020-06962-7

Other articles of this Issue 1/2020

BMC Cancer 1/2020 Go to the issue

Research article

Quantifying the under-estimation of cervical Cancer in remote regions of Tanzania

Research article

Emergence of spatio-temporal variations in chemotherapeutic drug efficacy: in-vitro and in-Silico 3D tumour spheroid studies

Research article

Prognostic value of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer: a systematic review and meta-analysis

Research article

Biplane transrectal ultrasonography plus ultrasonic elastosonography and contrast-enhanced ultrasonography in T staging of rectal cancer

Research article

Targeted nanopore sequencing for the identification of ABCB1 promoter translocations in cancer

Research article

The oncogenic potential of a mutant TP53 gene explored in two spontaneous lung cancer mice models
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits